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RANIBIZUMAB AND AFLIBERCEPT FOR
THE TREATMENT OF PIGMENT
EPITHELIAL DETACHMENT IN
NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION
Data from an Observational Study
ANAGHA VAZE, MBBS, MPHIL,* VUONG NGUYEN, PHD,* VINCENT DAIEN, MD, PHD,*
JENNIFER J. ARNOLD, MBBS,† STEPHANIE H. YOUNG, MBBS,‡ CHUI M. CHEUNG, FRCOPHTH,§¶
ECOSSE LAMOUREUX, MSC, PHD,§¶ MAYURI BHARGAVA, MBBS,§ DANIEL BARTHELMES, MD, PHD,*k
MARK C. GILLIES, MBBS, PHD* THE FIGHT RETINAL BLINDNESS STUDY GROUP
Purpose: To assess the effect of intravitreal ranibizumab and aﬂibercept on retinal
pigment epithelial detachment (RPED) in patients with neovascular age-related macular
degeneration.
Methods: This was a retrospective analysis of data from a prospectively designed and
implemented clinical audit. Analysis included change in RPED dimensions and visual acuity
in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and
RPED 6 months after treatment with either aﬂibercept or ranibizumab.
Results: There was no signiﬁcant between-group difference in the adjusted mean
change for maximum RPED height (P = 0.195), diameter (P = 0.522) or visual acuity
(P = 0.836) at 6 months. Injection frequency was the only clinical variable that affected
RPED height (P = 0.050) and visual acuity change for both treatment groups (P = 0.004).
Around 30% of eyes in each group had complete resolution of RPED at 6 months.
Conclusion: Eyes with neovascular age-related macular degeneration and RPED showed
signiﬁcant functional and anatomical responses after 6 months of intravitreal anti–vascular
endothelial growth factor injections. However, we found no signiﬁcant difference in
anatomical response or change in visual acuity between eyes treated with ranibizumab
compared with aﬂibercept. Larger, prospectively designed, randomized studies with longer
term follow-up may identify a difference between the two drugs that we did not detect.
RETINA 0:1–8, 2017
Retinal pigment epithelial detachment (RPED) fromthe underlying Bruch membrane is a well-known
feature of neovascular age-related macular degenera-
tion (nAMD). Its pathophysiology is however poorly
understood and treatment can be challenging.1 Vascu-
larized RPEDs occur in conjunction with choroidal
neovascularization with ﬁbrovascular material or
hemorrhage accumulating within the RPED.2
Rips can complicate vascularized RPEDs,3 and sub-
foveal RPEDs have been associated with a worse
visual prognosis.4 Previous studies have shown that
RPEDs in nAMD respond poorly to most treatments
including photodynamic therapy.5 Anti–vascular
endothelial growth factor (VEGF) agents have shown
variable responses.5–10 Spectral domain optical
coherence tomography (SD-OCT) has been used to
identify and provide more detailed anatomical
assessment of RPEDs. These have been deﬁned as
“any separation of RPE from Bruch membrane as seen
on SD-OCT” and their reﬂective properties have been
shown to predict their response to anti-VEGF therapy.11
Ranibizumab and aﬂibercept are the two most
common anti-VEGF drugs for the treatment of nAMD.
Although VEGF-A, a member of the VEGF family, is
1
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the key player in the pathogenesis of nAMD, there is
some evidence that placental growth factor (PlGF,
another member of the VEGF family) may also be
implicated in the pathogenesis of choroidal neovascu-
larization.12 Hence, because of different pharmacolog-
ical characteristics, ranibizumab and aﬂibercept may
have different treatment responses in speciﬁc sub-
groups. Although ranibizumab acts as antibody against
all isoforms of VEGF-A, the decoy-receptor action of
aﬂibercept allows for binding and thus blocking of not
only VEGF-A but also VEGF-B and placenta induced
growth factor.13
To date, there is limited information on the
comparative efﬁcacy of ranibizumab and aﬂibercept
in terms of RPED resolution, RPE tear rates, and
visual acuity (VA) improvement in nAMD eyes with
RPED. The aim of this study was to study the effect of
intravitreal ranibizumab and aﬂibercept on these
RPED dimensions after 6 months of treatment in
patients with nAMD.
Methods
This was a retrospective analysis of data from
a prospectively designed and implemented clinical
audit14 performed in four centers: three in Sydney,
Australia, and 1 in Zurich, Switzerland. The study
was approved by the South Eastern Sydney Local
Health District, the Ethics Committee of the Canton
of Zurich, and performed in accordance with the
ethical standards of the Declaration of Helsinki.
We identiﬁed a consecutive case series of treatment-
naive patients with nAMD with RPED who started
treatment with either aﬂibercept or ranibizumab from
October 1, 2013 (the date from which aﬂibercept was
used in the above centers), until November 1, 2015.
The Fight Retinal Blindness! database, the details of
which have been published previously,14 was used to
identify patients. Patients who had been diagnosed
with idiopathic polypoidal choroidal vasculopathy or
retinal angiomatous proliferation or who had received
other adjuvant treatment modalities in the study eye
such as photodynamic therapy after the start of anti-
VEGF therapy were automatically excluded during the
database analysis. A retinal specialist (A.V.) examined
the baseline OCTs of all eyes and thus identiﬁed the
inclusion criteria, which were as follows: presence of
RPED at baseline deﬁned as “any separation of RPE
from Bruch membrane as seen on SD-OCT” that was
not drusenoid within the central 6 · 6 cube; presence
of a follow-up OCT on or after 22 weeks; OCT images
of sufﬁcient quality at both baseline and follow-up to
allow analysis; and eyes having monotherapy with
either aﬂibercept or ranibizumab throughout the 6
months of follow-up. Exclusion criteria were poor
image quality, presence of pigment epithelial tear at
baseline, polypoidal choroidal vasculopathy, or any
other confounding retinopathies or use of other
adjuvant treatment modalities in the study eye such
as photodynamic therapy/laser after the start of anti-
VEGF therapy.
Baseline examination and 6 months follow-up visits
included evaluation of VA measured on a standard
logarithm of the minimal angle of resolution chart,
with their current spectacles if worn and pin hole, with
the highest value entered. An ophthalmic examination
included dilated fundoscopy, SD-OCT, and ﬂuores-
cein angiography; the last was usually performed only
at baseline on all cases. Treatments were given
completely at the discretion of the practitioner in
consultation with their patient, thereby reﬂecting real-
world practice.
The assessment was performed by an independent
reading center (Singapore Eye Research Institute)
masked to the treatment arms. SD-OCT was used to
examine the maximum RPED dimensions at baseline
and after 6 months of treatment (ﬁrst OCT after 22
weeks). OCT with cube examination was performed
using either the Spectralis (Heidelberg Engineering,
Heidelberg, Germany) or Cirrus (Carl Zeiss Meditec,
Inc, Oberkochen, Germany), and the same machine
was used at baseline and at 6 months. The following
data were recorded, with the grader being masked for
drug type, using the caliper provided by the manufac-
turer’s software: maximum RPED height (vertical dis-
tance from Bruch membrane to the RPE border) and
maximum horizontal diameter of RPE elevation. Man-
ual adjustment of the segmentation line was performed
where required. Retinal pigment epithelial detachments
were graded as hollow, solid, or mixed based on their
SD-OCT reﬂectivity at baseline according to the
method previously described by Punjabi et al.11
Spectral domain optical coherence tomography at base-
line was also used to classify them into subfoveal,
juxtafoveal, or extrafoveal depending on the location
(subfoveal—RPED is under the center of the foveal
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depression, juxtafoveal—if RPED lies in an area 1 mm–
250 mm from the fovea, extrafoveal—if the RPED lies
beyond 250 mm from the center or the fovea).
Our primary outcome measure was the change in
RPED dimensions (maximum RPED height and
maximum horizontal diameter) in micrometers after
6 months of treatment in each group. The secondary
outcome measure was the change of VA at 6 months.
Descriptive statistics included the mean, SD,
median, interquartile range, and percentages where
appropriate. Baseline characteristics were compared
between treatment arms using Student t, Wilcoxon
rank-sum, chi-square, and Fisher tests where appropri-
ate. Comparison of RPED and VA outcomes at 6
months between the groups receiving ranibizumab or
aﬂibercept was analyzed using regression models, with
the change in RPED height, RPED diameter, and the
change in VA as the outcome variables, treatment arm
as the primary predictor variable, adjusted for baseline
age, baseline RPED dimensions, and VA. Appropriate
conversion formulae were used to make measurement
adjustments in tabulating aggregate results generated
by different OCT (Cirrus and Spectralis) machines
before performing statistical calculations.15 Clinical
characteristics including injection frequency within
the 6 months of treatment, angiographic size and sub-
type at baseline, and RPED reﬂectivity (hollow,
mixed, or solid) and location on SD-OCT (extrafoveal,
juxtafoveal, or subfoveal) at baseline were also
included in the regression model and their effects on
RPED outcomes investigated. These models were also
used to estimate adjusted (least squares) mean values
correcting for differences in baseline characteristics
between treatment groups. Within-group change in
RPED and VA outcomes were analyzed using paired
t tests. The number of injections and visits were com-
pared by a Poisson regression model with an offset for
log days follow-up. Tests for proportions were
compared using the chi-square test where appropriate.
Correlations between injection frequency and change
in RPED dimensions and VA were analyzed using
Pearson correlations (r). A P , 0.05 was considered
statistically signiﬁcant. All analyses were performed
using R version 3.2.4.16
Results
We identiﬁed 233 eyes from 215 patients beginning
monotherapy treatment with ranibizumab or aﬂiber-
cept at the four centers. The 97/233 (42%) eyes with
RPED that met eligibility criteria were graded by the
reading center. Of these 97 eyes, 63 (65%) were also
part of a previous study comparing 12-month visual
outcomes for ranibizumab and aﬂibercept.17 Retinal
pigment epithelial detachment dimensions for ﬁve
eyes were marked as ungradable because of poor
image quality at either 1 or both visits and were
excluded from the analysis. Statistical analyses are
thus based on 92 eyes. From previously published
data, we estimated that the rate of eyes switching ther-
apy in the ﬁrst 6 months of treatment was 11.7% for
ranibizumab to aﬂibercept and 2.6% from aﬂibercept
to ranibizumab. Noncompletion rates were estimated
to be similar in the ﬁrst 6 months of treatments (10.7%
for both drugs and these rates are for the overall cohort
of exudative AMD).17 The treatment strategy was treat
and extend for all the centers included with 82.8% and
81.3% of the visits being injection visits for ranibizu-
mab and aﬂibercept, respectively. A majority of eyes
were examined using the Spectralis SD-OCT machine
(Table 1); thus all measurements were converted to
Spectralis measurements.
Demographic Characteristics
The demographic characteristics for the 92 patients
included in the analysis are summarized in Table 1.
Patients treated with ranibizumab were signiﬁcantly
older than aﬂibercept-treated patients (84.1 years vs.
78.2 years, P , 0.001). Those treated with aﬂibercept
had a mean larger maximum RPED diameter compared
with ranibizumab (2,170 mm vs. 1,735 mm, P = 0.033),
although maximum RPED height was similar between
the 2 groups (230 mm vs. 263 mm, for ranibizumab for
aﬂibercept, respectively; P = 0.242). There were more
extrafoveal and juxtafoveal RPEDs in ranibizumab-
treated patients, whereas aﬂibercept-treated patients
had more subfoveal RPEDs (P = 0.047).
Ranibizumab-treated patients also had more predomi-
nantly classic lesions, whereas aﬂibercept-treated
patients had more occult lesions (P = 0.045).
Retinal Pigment Epithelial Detachment Outcomes
at 6 Months
Outcomes at 6 months for the ranibizumab and
aﬂibercept treatment arms are summarized in Table 2.
There was no signiﬁcant between-group difference
(P . 0.05) in the adjusted mean change {mean (95%
conﬁdence interval [CI])} for maximum RPED height
at 6 months for ranibizumab (2107.9 mm [2157.3,
258.4]) and aﬂibercept (269.6 mm [2116.5,
222.6]), although both groups recorded signiﬁcant
within-group changes (P , 0.001 for both treatment
groups). Within-group change (mean [95% CI]) in
maximum RPED height for PED types in both treat-
ment groups combined was signiﬁcant for hollow
(2129.7 mm [2172.1, 287.2] P , 0.001) and solid
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PEDs (267.8 mm [2111.7, 223.8]; P = 0.004) but not
mixed PEDs (268.5 [2139.3, 2.3]; P = 0.057). Injec-
tion frequency was the only clinical variable to have
a signiﬁcant impact on RPED height (P = 0.050), with
a weak correlation between more frequent injections
and greater reductions in RPED height (r = 20.17;
P = 0.097). Thirty-one of 92 patients (34%) had com-
plete resolution of PED at 6 months (40% for ranibizu-
mab vs. 28% for aﬂibercept; P = 0.299). None of the
baseline characteristics had a statistically signiﬁcant
impact on the complete resolution of RPED (Table 3).
The adjusted mean change (95% CI) in maximum
RPED diameter was 2634.8 mm (21,082.9, 2186.6)
for ranibizumab and 2462.6 mm (2890.2, 235.0) for
aﬂibercept (P = 0.522). Within-group changes in max-
imum RPED diameter were statistically signiﬁcant for
both ranibizumab (P = 0.002) and aﬂibercept (P ,
0.001). Within-group change (mean [95% CI]) in max-
imum RPED height for PED types in both treatment
groups combined was signiﬁcant for hollow (2623.0
mm [2953.6, 2292.4]; P , 0.001) and solid PEDs
(2554.9 mm [2915.1, 2194.7]; P = 0.004) but not
mixed PEDs (2614.1 [21,354.0, 125.9]; P = 0.096).
There were no signiﬁcant predictors of maximum
RPED diameter change at 6 months.
Visual Acuity Outcomes at 6 Months
The adjusted mean improvement (95% CI) in VA
was 6.5 letters (2.6, 10.4) for ranibizumab and 7.0
letters (3.3, 10.7) for aﬂibercept, with no signiﬁcant
difference between the 2 treatments (P = 0.836).
Within-group change in VA was signiﬁcant for both
ranibizumab (P = 0.002) and aﬂibercept (P , 0.001).
Injection frequency was the only clinical variable to
have a signiﬁcant impact on VA change for both
treatment groups (P = 0.004) with more frequent in-
jections correlated with greater gains in VA (r = 0.26;
P = 0.012).
Injections and Visits
The mean number of injections (4.7 vs. 4.9; P =
0.862) and visits (5.1 vs. 5.3; P = 0.855) did not differ
between ranibizumab- and aﬂibercept-treated patients.
Adverse Events
Only 2 eyes were recorded as developing an RPE
tear within the 6-month follow-up period; 1 was
treated with ranibizumab and the other with
aﬂibercept.
Table 1. Comparison of Baseline Demographic Characteristics of Patients With PED at Baseline Between Treatment Arms
Ranibizumab Aﬂibercept P
No. of patients 42 50
Baseline age, years, mean (SD) 84.1 (6.4) 78.2 (8.0) ,0.001
Female (%) 67 62 0.805
Left eye (%) 38 52
Baseline VA (letters), mean (SD),
(approximate Snellen equivalent)
63.1 (20.4), (20/502) 57.8 (19.8), (20/632) 0.210
Baseline maximum RPED height,
mean (SD), microns
230.0 (107.2) 262.6 (156.8) 0.242
Baseline maximum RPED diameter,
mean (SD), microns
1,734.6 (895.4) 2,170.4 (1,009.2) 0.033
RPED reﬂectivity, n (%)
Hollow 23 (55) 26 (52) 0.491
Mixed 4 (10) 9 (18)
Solid 15 (36) 15 (30)
Location of RPED on SD-OCT, n (%)
Extrafoveal 13 (31) 10 (20) 0.047
Juxtafoveal 11 (26) 6 (12)
Subfoveal 18 (43) 34 (68)
Baseline greatest linear dimension,
median (interquartile range)
2,561 (1,958–3,557) 3,122 (1,863–4,402) 0.267
Angiographic subtype, n (%)
Occult 25 (60) 39 (78) 0.045
Minimally classic 4 (10) 3 (6)
Predominantly classic 11 (26) 4 (8)
Unknown 2 (5) 4 (8)
SD-OCT machine, n (%)
Cirrus 23 (55) 16 (32) 0.047
Spectralis 19 (45) 34 (68)
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Discussion
In this study, we found that treatment-naive eyes
with nAMD and RPED showed signiﬁcant anatomical
and functional responses to intravitreal anti-VEGF
injections of either ranibizumab or aﬂibercept after
6 months of treatment. Injection frequency was the
only variable found to have a signiﬁcant impact on
RPED height, with a weak correlation between more
frequent injections and greater reductions in RPED
height and diameter. More frequent injections were
also found to have greater gains in VA. However, we
did not ﬁnd signiﬁcant differences between the two
drugs in either anatomical or functional outcomes. We
found complete resolution of RPED in 42% cases.
Neither the drug type nor any baseline characteristic
independently predicted the complete resolution of
eyes with RPED or improved VA.
We used regression analysis to estimate event rates
in the primary analysis to account for the baseline
differences between the two groups. Eyes receiving
ranibizumab were signiﬁcantly older (mean 82 years
vs. 78 years), had somewhat smaller lesions
(1,735 mm vs. 2,170 mm diameter), were more likely
to be extrafoveal, and have a classic component. The
difference in age is likely because of concerns ex-
pressed soon after aﬂibercept had been approved that
it might confer a higher risk of thromboembolic
events.18 Larger lesions might point to aﬂibercept
being used for more advanced lesions, although its
greater use for occult lesions may not be consistent
with this.
Previous studies have reported the response of anti-
VEGF treatment in patients with nAMD with RPED.
The CATT subanalysis identiﬁed total foveal thickness
and retinal pigment epithelium elevation on time-
domain OCT as baseline anatomical predictors of
VA outcomes at month 12.4 However, RPEDs were
not identiﬁed as signiﬁcant covariates for treatment
response in a subanalysis of HARBOR.19 Ach et al7
previously showed a nonsigniﬁcant decrease in PED
height with bevacizumab for vascularized RPEDs over
a period of 9 months (mean height decrease: 81.7 mm,
P . 0.05; follow-up 37.9 ± 18.3 weeks). The VIEW 1
and 2 trials of nAMD reported that patients treated
with aﬂibercept had higher rates of RPED ﬂattening
than those treated with ranibizumab (Shah CP, et al.
AAO 2013; Poster PA088). Differences between our
ﬁndings and previous work could be attributed to the
use of different drugs, measurement techniques
(SD-OCT was used in HARBOR and time-domain
OCT was used in CATT), treatment protocols, and
small sample sizes. In studies of treatment-naive vas-
cularized RPEDs, Panos et al10 observed a reduction in
mean PED height of 135 mm after pro re nata ranibi-
zumab for 12 months; their results were not dissimilar
to those presented here (unadjusted mean of 96 mm for
ranibizumab, 105 mm for aﬂibercept).
Other studies have reported the effect of switching
treatment from ranibizumab to aﬂibercept on RPEDs.
Table 2. Comparison of Outcomes at 6 Months Between Treatment Arms and Resulting P values
Ranibizumab Aﬂibercept P
No. of eyes 42 50
PED resolved, n (%) 17 (40) 14 (28) 0.299
Maximum RPED height
Baseline (SD) 230.0 (107.2) 262.6 (156.8)
Final (SD) 134.2 (132.3) 157.5 (153.3)
D (95% CI) 295.8 (2133.2 to 258.4) 2105.1 (2147.8 to 262.3)
Adjusted D (95% CI) 2107.9 (2157.3 to 258.4) 269.6 (2116.5 to 222.6) 0.195
Maximum RPED diameter
Baseline (SD) 1,734.6 (895.4) 2,170.4 (1,009.2)
Final (SD) 1,194.1 (1,256.8) 1,520.2 (1,328.6)
D (95% CI) 2540.6 (2872.9 to 2208.3) 2650.1 (2968.5 to 2331.8)
Adjusted D (95% CI) 2634.8 (21,082.9 to 2186.6) 2462.6 (2890.2 to 235.0) 0.522
BCVA
Baseline (SD), (approximate
Snellen equivalent)
63.1 (20.4), (20/502) 57.8 (19.8), (20/632)
Final (SD), (approximate Snellen
equivalent)
68.4 (22.4), (20/402) 66.3 (15.4), (20/50+)
D (95% CI) 5.3 (2.1 to 8.5) 8.5 (5.2 to 11.9)
Adjusted D (95% CI) 6.5 (2.6 to 10.4) 7.0 (3.3 to 10.7) 0.836
Injections (range) 4.7 (1 to 7) 4.9 (1 to 7) 0.862
Visits (range) 5.1 (2 to 7) 5.3 (2 to 7) 0.855
Adjusted DRPED and DBCVA outcomes are the least-squared mean values after adjusting for differences in baseline characteristics
between the treatment groups.
BCVA, best-corrected visual acuity.
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Kumar et al reported the results of switching treatments
in a group of eyes with nAMD, 97% of which had
RPED.20 They found a signiﬁcant change in maximum
RPED height and central retinal thickness 3 months
after switching from ranibizumab to aﬂibercept but no
change in VA. In a small case series, Patel et al reported
dramatic resolution of RPEDs after switching from ra-
nibizumab to aﬂibercept.5 However, these studies were
case series with sample sizes as small as 34 and 3 eyes.
Chan et al, in a retrospective study of 189 eyes that
switched to aﬂibercept from either ranibizumab or bev-
acizumab or mixed treatment have reported improved
anatomical and functional outcomes 6 months after
transition. However, the more robust response in the
eyes with PED (n = 102) as compared to eyes without
PED was thought to be due to a relative ceiling effect of
certain OCT variables in eyes without PED because
subretinal ﬂuid height and volume was substantially
lower in eyes without PED than in eyes with PED.21
Broadhead et al recently reported that aﬂibercept was
effective in reducing RPED size in previously treatment-
resistant patients who were treated with ranibizumab.
However, similar to other studies, reduction in RPED
size did not correlate with improved VA in their study.8
A recent study by Dirani et al is one of the few
reports of the comparative efﬁcacy of ranibizumab and
aﬂibercept on RPEDs associated with newly diag-
nosed nAMD. They studied the effect of three
injections of either drug on these patient and reported
signiﬁcant anatomical and functional responses to
intravitreal anti-VEGF injections of either ranibizumab
or aﬂibercept.22 Multivariate analysis revealed that VA
improvement was associated with lower VA at base-
line (P = 0.001) and the presence of subretinal ﬂuid
(P = 0.001). The degree of RPED reduction was asso-
ciated with RPED height at baseline (P = 0.001), pre-
dominantly serous RPEDs (P = 0.003), and use of
aﬂibercept (P = 0.022). As in this study, drug type
was not associated with change in VA at 3 months
in this study.
We studied the effect of these two drugs on
treatment-naive nAMD eyes with RPED 6 months
after starting treatment. Because RPEDs generally
require prolonged anti-VEGF treatment for optimal
response,6,7,10 we studied 6-month outcomes of the 2
anti-VEGF drugs rather than just the loading phase of
3 injections. Similar to the study by Dirani et al, our
study found a signiﬁcant reduction in RPED dimen-
sions with both ranibizumab and aﬂibercept treatment.
However, our study did not ﬁnd a stronger effect of
aﬂibercept on ﬂattening of the RPED as reported by
other studies.22,23
Table 3. Summary of Characteristics of Eyes That Had Complete Resolution of PED Compared With Those That Did Not
Resolved Unresolved P
No. of patients 31 61
Treatment arm, n (%)
Ranibizumab 17 (55) 25 (41) 0.299
Aﬂibercept 14 (45) 36 (59)
Baseline age, mean (SD) 80.0 (7.5) 81.3 (8.1) 0.452
Female (%) 61 66 0.861
Baseline VA, mean (SD),
(approximate Snellen equivalent)
65.0 (17.2), (20/50) 57.8 (21.2), (20/632) 0.086
VA change, mean (95% CI) 8.4 (5.0–11.8) 6.4 (3.3–9.4) 0.371
Baseline maximum RPED height,
mean (SD)
262.9 (103.0) 240.0 (151.2) 0.395
Baseline maximum RPED diameter,
mean (SD)
1,772.0 (842.2) 2,064.6 (1,031.0) 0.155
RPED reﬂectivity, n (%)
Hollow 17 (55) 32 (52) 1.000
Mixed 4 (13) 9 (15)
Solid 10 (32) 20 (33)
Location on SD-OCT, n (%)
Extrafoveal 10 (32) 13 (21) 0.460
Juxtafoveal 6 (19) 11 (18)
Subfoveal 15 (48) 37 (31)
Baseline GLD, median (interquartile
range)
2,656 (2,025, 4,168) 2,824 (1,936, 4,100) 0.882
Angiographic subtype, n (%)
Occult 22 (71) 42 (69) 0.582
Minimally classic 1 (3) 6 (10)
Predominantly classic 6 (19) 9 (15)
Unknown 2 (6) 4 (7)
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Previous studies have suggested that RPED type
based on its OCT reﬂectivity may be an important
characteristic that predicts response to ther-
apy.8,9,11,22 We also found that hollow RPEDs re-
sponded better to anti-VEGF treatment. However,
there was no statistically signiﬁcant difference in
the effect of the two treatments on RPED dimensions
or VA outcomes. We found good VA improvement
regardless of the drug type, similar to other studies.22
None of the other baseline characteristics seemed to
have any inﬂuence on the functional outcomes in our
study. However, previous studies have suggested that
functional long-term prognosis of RPED is generally
poor, even with anti-VEGF therapy.24,25 Vascular-
ized RPEDs and baseline RPED height have been
reported to be associated with poor functional out-
comes,26–28 but we have not replicated this ﬁnding
in this 6-month study.
Our study has several limitations. Numbers were not
large, at around 50 eyes per group: it is possible that
a larger study may have found signiﬁcant differences
between groups that were not apparent in this study.
We cannot exclude the possibility that clinicians chose
a certain drug for a speciﬁc clinical presentation of
RPED. Personal preference and previous experience
with either of the drugs may have inﬂuenced treatment
choices in such cases, for example aﬂibercept may
have been used in cases with more advanced RPEDs.
The signiﬁcantly larger greatest linear diameter of eyes
that were treated with aﬂibercept may be evidence of
this, although the difference was not very large.
Retinal pigment epithelial detachment dimensions
were assessed using maximum RPED height and
width as surrogate markers, as have most previous
studies.5,7,8,11 Although quantitative changes in RPED
volume using SD-OCT automated software have been
proposed as a predictor of RPED response,29 the auto-
mated “RPED elevation” software shows poor agree-
ment with manual measurements becauseof a high rate
of segmentation line breakdown.30 Hence, further
development of software to analyze RPED morphol-
ogy better is needed to ensure more accurate quantiﬁ-
cation of RPEDs. One other potential limitation was
the short follow-up duration in this study. This analy-
sis included only patients who completed 6 months of
monotherapy and could have overestimated the out-
come in eyes with RPED. Based on previous analy-
ses,17 switching rates were low but biased in favor of
ranibizumab to aﬂibercept switching, whereas non-
completion rates were similar between the two drugs.
Studies among patients having PED with long-term
follow-up are necessary to conﬁrm our results. Also,
we cannot rule out the possibility of an asymmetri-
cal distribution of idiopathic polypoidal choroidal
vasculopathy between both drug groups because of
the lack of routine performance of indocyanine green
angiography reﬂecting the real-world practice in the
studied population, but it is likely not a an important
confounding factor given the fact that idiopathic poly-
poidal choroidal vasculopathy is an uncommon type of
neovascular lesion in the studied population.
In conclusion, treatment-naive patients with nAMD
and RPED showed signiﬁcant anatomical and func-
tional improvements at 6 months with both intravitreal
ranibizumab or aﬂibercept injections. Injection
frequency was the only variable that had a signiﬁcant
impact on the anatomical response, especially on
RPED height and VA outcomes. There was no
signiﬁcant difference between the two drugs in
anatomical response in terms of reduction in RPED
height and width or functional response. Larger and
prospectively designed studies with longer term
follow-up may be needed to understand better the
inﬂuence of baseline characteristics and whether there
is a difference in treatment responses between the two
drugs.
Key words: age-related macular degeneration,
vascular endothelial growth factor inhibitors, retinal
pigment epithelial detachment.
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